Back
Halozyme Therapeutics Stock Price Chart
America's enemies are regrouping & it may sucker punch your savings
Click here to learn more.
Sell
39
HALO
Halozyme Therapeutics
Last Price:
45.65
Seasonality Move:
17.03%
7 Day Trial
ALL ACCESS PASS
$
7
Trump's IRS Hands Massive 'Victory Gift' To 401K Owners
Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.- Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.
Halozyme Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 57.53 | Sell |
| 20-day SMA: | 54.48 | Sell |
| 50-day SMA: | 56.18 | Sell |
| 200-day SMA: | 48.93 | Sell |
| 8-day EMA: | 55 | Sell |
| 20-day EMA: | 55.41 | Sell |
| 50-day EMA: | 55.64 | Sell |
| 200-day EMA: | 50.73 | Sell |
Halozyme Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.02 | Sell |
| Relative Strength Index (14 RSI): | 30.2 | Sell |
| Chaikin Money Flow: | -7140517 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (49.94 - 58.56) | Sell |
| Bollinger Bands (100): | (52.16 - 60.38) | Sell |
Halozyme Therapeutics Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 45.65 while HALO 8-day simple moving average is 57.53, which is a Sell signal.
- The stock price of HALO is 45.65 while Halozyme Therapeutics 20-day SMA is 54.48, which makes it a Sell.
- Halozyme Therapeutics 50-day simple moving average is 56.18 while HALO share price is 45.65, making it a Sell technically.
- HALO stock price is 45.65 and Halozyme Therapeutics 200-day simple moving average is 48.93, creating a Sell signal.
HALO Technical Analysis vs Fundamental Analysis
Sell
39
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a Sell
The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
5.81B
Price in USD:
45.65
Share Volume:
7.23M
Halozyme Therapeutics 52-Week Range
52-Week High:
65.53
52-Week Low:
33.15
Sell
39
Halozyme Therapeutics (HALO)
is a Sell
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?
The Halozyme Therapeutics stock price is 45.65 USD today. -
Will HALO stock go up or go down?
Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Halozyme Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is overvalued.
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 45.65 while HALO 8-day exponential moving average is 55.00, which is a Sell signal.
- The stock price of HALO is 45.65 while Halozyme Therapeutics 20-day EMA is 55.41, which makes it a Sell.
- Halozyme Therapeutics 50-day exponential moving average is 55.64 while HALO share price is 45.65, making it a Sell technically.
- HALO stock price is 45.65 and Halozyme Therapeutics 200-day simple moving average is 50.73, creating a Sell signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
- HALO Moving Average Covergence Divergence (MACD) indicator is -0.02, suggesting Halozyme Therapeutics is a Sell
- Halozyme Therapeutics Relative Strength Index (RSI) is 30.2, which suggest Halozyme Therapeutics is oversold
- The Bollinger Bands (25) for Halozyme Therapeutics is (49.94 - 58.56), which suggest Halozyme Therapeutics is a Sell
- The Bollinger Bands (100) for Halozyme Therapeutics is (52.16 - 60.38), which suggest Halozyme Therapeutics is a Sell
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.